'No excuse': ICER determines AstraZeneca's new moneymaker Soliris is vastly overpriced
The ink has barely dried on AstraZeneca’s $39 billion deal to swallow Alexion back in July. But independent drug watchdog ICER has been crunching …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
